## SUMMARY

**[0002a]** In one aspect, the present disclosure provides use of TG02, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating a patient having cancer, wherein therapeutically effective amounts of TG02, or a pharmaceutically acceptable salt thereof, are to be administered to the patient with radiotherapy or temozolimide.

**[0003]** In one example, the present disclosure provides therapeutic methods of treating a cancer patient, the methods comprising administering to the patient a therapeutically effective amount of TG02. In another example, the patient's cancer is characterized as overexpressing of MYC, MCL1, or both.

**[0004]** In another example, the present disclosure provides therapeutic methods of treating a cancer patient, the methods comprising administering to the patient therapeutically effective amounts of TG02 and an immune checkpoint inhibitor, e.g., a PD-1 inhibitor, a PD-L1 inhibitor, a CTLA-4 inhibitor, a LAG3 inhibitor, a TIM3 inhibitor, or a cd47 inhibitor.

**[0005]** In another example, the present disclosure provides therapeutic methods of treating a cancer patient, the methods comprising administering to the patient therapeutically effective amounts of TG02 and a COX inhibitor, e.g., apricoxib or 6-bromo-8-(methyl-D3)-2-(trifluoromethyl)-2H-chromene-3-carboxylic acid.

**[0006]** In another example, the present disclosure provides therapeutic methods of treating a cancer patient, the methods comprising administering to the patient therapeutically effective amounts of TG02, an immune checkpoint inhibitor, and a COX-2 inhibitor.

**[0007]** In another example, present disclosure provides therapeutic methods of treating a cancer patient who has tumors that overexpress MYC, MCL1, or both.

**[0008]** In another example, the present disclosure provides kits comprising TG02, TG02 and an immune checkpoint inhibitor, TG02 and a COX-2 inhibitor, and TG02 and an immune checkpoint inhibitor and a COX-2 inhibitor.

**[0009]** In another example, the present disclosure provides a pharmaceutical composition comprising TG02, a COX-2 inhibitor, e.g., apricoxib or 6-bromo-8-(methyl-D3)-2-(trifluoromethyl)-2H-chromene-3-carboxylic acid and a pharmaceutically acceptable excipient.

## BRIEF DESCRIPTION OF DRAWINGS

**[0010]** Fig. 1 is a bar graph showing the *in vitro* activity of TG02, TMZ (temozolomide), and TG02 + TMZ in GSC923 cells.